Eisai announces Phase 3 Lenvima combination trial analyses in advanced kidney cancer at ESMO 2026
Eisai will present final Phase 3 LITESPARK-011 results for advanced kidney cancer at ESMO in Madrid on October 25, 2026. The study supported recent FDA clearance of Welireg with Lenvima for adults with advanced clear-cell kidney cancer previously treated with immunotherapy. LITESPARK-012 findings, also scheduled for Oc